Wendy Young Biography and Net Worth

Director of Rapport Therapeutics

Wendy Young serves as a board member and scientific advisor at several biotech companies and is an advisor at Google Ventures. Previously, Dr. Young was the senior vice president, small molecule drug discovery at Genentech where she actively built and led the research & discovery organization. Under her leadership, more than 25 clinical candidates progressed into development. Additionally, Dr. Young led the BTK discovery program and is co-inventor of fenebrutinib, which is currently in Phase 3 trials for multiple sclerosis. Prior to joining Genentech, Dr. Young held roles of increasing scientific leadership at Celera Genomics and Scios, a J&J company. She is an inventor and/or author on more than 70 published patents and manuscripts.

What is Wendy B. Young's net worth?: The estimated net worth of Wendy B. Young is at least $272.65 thousand as of September 11th, 2025. Dr. Young owns 9,500 shares of Rapport Therapeutics stock worth more than $272,650 as of December 5th. This net worth evaluation does not reflect any other assets that Dr. Young may own. Learn More about Wendy B. Young's net worth.
How do I contact Wendy B. Young?: The corporate mailing address for Dr. Young and other Rapport Therapeutics executives is , , . Rapport Therapeutics can also be reached via phone at (857) 321-8020 and via email at [email protected]. Learn More on Wendy B. Young's contact information.
Has Wendy B. Young been buying or selling shares of Rapport Therapeutics?: Wendy B. Young has not been actively trading shares of Rapport Therapeutics during the past quarter. Most recently, on Thursday, September 11th, Wendy B. Young bought 3,500 shares of Rapport Therapeutics stock. The stock was acquired at an average cost of $22.60 per share, with a total value of $79,100.00. Following the completion of the transaction, the director now directly owns 9,500 shares of the company's stock, valued at $214,700. Learn More on Wendy B. Young's trading history.
Who are Rapport Therapeutics' active insiders?: Rapport Therapeutics' insider roster includes James Healy (Director), Troy Ignelzi (CFO), and Wendy Young (Director). Learn More on Rapport Therapeutics' active insiders.
Are insiders buying or selling shares of Rapport Therapeutics?: During the last year, Rapport Therapeutics insiders bought shares 3 times. They purchased a total of 19,400 shares worth more than $240,350.00. During the last year, insiders at the sold shares 12 times. They sold a total of 145,752 shares worth more than $3,558,621.23. The most recent insider tranaction occured on November, 17th when CEO Abraham Ceesay sold 5,833 shares worth more than $146,933.27. Insiders at Rapport Therapeutics own 13.6% of the company. Learn More about insider trades at Rapport Therapeutics.
Information on this page was last updated on 11/17/2025.

Wendy B. Young Insider Trading History at Rapport Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/11/2025	Buy	3,500	$22.60	$79,100.00	9,500
3/12/2025	Buy	6,000	$10.21	$61,260.00	6,000

Wendy B. Young Buying and Selling Activity at Rapport Therapeutics

Rapport Therapeutics Company Overview

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Today's Range

Now: $28.70

$27.38

$29.32

50 Day Range

MA: $26.90

$24.37

$30.36

2 Week Range

Now: $28.70

$6.43

$42.27

Volume

474,346 shs

Average Volume

362,428 shs

Market Capitalization

$1.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63